On May 26, according to the BBC report, the British National Health Service (NHS) will start using the antiviral drug Remdesivir for some patients with new coronary pneumonia.

British Health Minister Matt Hancock said that this may be the biggest step in treatment since the new coronary pneumonia epidemic crisis occurred.

According to the information published on the official website of the British Medicines and Health Products Regulatory Agency (MHRA) on the same day, MHRA ’s Use gave a positive scientific opinion (scientific opinion), this step will support the use of redoxivir in the treatment of patients with severe new pneumonia, including adults and adolescents.

MHRA explained that the purpose of the “Early Drug Acquisition Program (EAMS)” is to make patients whose lives are at risk or severely debilitated, but fail to meet existing medical needs If satisfied, obtain the use of drugs that have not been officially licensed.

MHRA said that during the “Early Medicine Early Access Program (EAMS)”, Gilead will provide Ridesivir to the NHS free of charge. Reduxilvir will continue to conduct clinical trials. MHRA has approved several clinical trials to evaluate the role of reduxilvir and is currently in progress.


The United Kingdom supports the treatment of neocoronal pneumonia with redoxir Speaking at a press conference, Radexivir has achieved encouraging early trial results. If the trial in the UK is successful, then health officials will give priority to using Radecivir for treatment.

According to the BBC report, Dr. Stephen Griffin of the University of Leeds School of Medicine in the United Kingdom said that Ridesivir may be the most promising antiviral drug to treat new coronary pneumonia . He said that suffering from strictSeriously ill patients will likely be treated first with Redisilvir, “Obviously this is the most ethical practice, but it also means that we cannot expect the drug to work magically immediately.”

“We can hope that Radecivir improves the recovery rate and benefits as many patients as possible.” Stephen Griffin said.

Redoxivir is an antiviral drug under development developed by Gilead Sciences, the earliest used to treat Ebola virus In the future, it has shown certain potential in the treatment of new coronary pneumonia, and many countries are conducting clinical trials on the treatment of new coronary pneumonia with redoxivir.

On April 29th, the director of the National Institute of Allergy and Infectious Diseases (NIAID), Fuch said that a randomized double-blind control of redisive in NIAID The trial showed a curative effect, which can moderately speed up the recovery of patients infected with new coronavirus.

Based on the above test results, on May 1, the US Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for the treatment of new coronary pneumonia . Japan has also “specially approved” redoxivir for the treatment of new coronary pneumonia on May 7.

But Redcive may not be a magic drug. The aforementioned NIAID test showed that in terms of reducing mortality, the redoxir treatment group did not show a significant difference from the control group, and only accelerated recovery time to a certain extent. During the same period, the results of clinical trials released by the Chinese team showed that no significant clinical benefit was observed in the combination of redoxivir and standard therapy compared with standard therapy.